What does this video actually claim?
Without being able to see the specific content of @liviermayoral's TikTok, we can only work with the hashtags provided: #tirzepatide #tirzepeptide #peptidos. The video appears to focus on tirzepatide, likely discussing its weight loss or diabetes management properties.
The misspelling of "tirzepeptide" instead of "tirzepatide" is common on social media. The Spanish hashtag "peptidos" suggests content aimed at Spanish-speaking audiences about peptide medications. These videos typically make claims about dramatic weight loss results or positioning tirzepatide as superior to other GLP-1 medications.
What's the real science on tirzepatide?
Tirzepatide works differently from pure GLP-1 agonists like semaglutide. It targets both GLP-1 and GIP receptors, which may explain its superior weight loss results in head-to-head trials.
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed impressive results: 22.5% average weight loss with the 15mg dose over 72 weeks. That's better than semaglutide's 14.9% weight loss in the STEP 1 trial. The SURPASS-2 trial (Frías et al., NEJM, 2021) directly compared tirzepatide to semaglutide and found tirzepatide was more effective for both weight loss and blood sugar control.
Starting doses begin at 2.5mg weekly, escalating to maximum doses of 15mg for weight management (Zepbound) or 15mg for diabetes (Mounjaro).
What do creators get wrong about tirzepatide?
Many TikTok videos oversell tirzepatide as a miracle drug or downplay side effects. The SURMOUNT trials showed that 89% of participants experienced gastrointestinal side effects, with 10% dropping out due to adverse events.
Creators often skip mentioning that the dramatic weight loss numbers come from clinical trials with strict dietary counseling and lifestyle interventions. Real-world results may differ significantly from trial outcomes.
Another common mistake is claiming tirzepatide works for everyone. In SURMOUNT-1, about 9% of participants lost less than 5% of their body weight, which researchers don't consider clinically meaningful. The drug simply doesn't work equally well for all patients.
What should you actually know about tirzepatide?
Tirzepatide represents the current gold standard for medication-assisted weight loss, but it's not magic. The average weight loss of 22.5% in trials is impressive, but that's an average over 72 weeks with comprehensive lifestyle support.
Cost remains a major barrier. Without insurance coverage, tirzepatide can cost over $1,000 monthly. The FDA approved it for weight management as Zepbound in November 2023, but insurance coverage varies widely.
Like all GLP-1 medications, tirzepatide requires ongoing use to maintain benefits. The SELECT trial showed that people regain about two-thirds of lost weight within one year of stopping treatment. This isn't a quick fix but a long-term medication commitment.